(Q44795969)

English

Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity

scientific article published on 28 February 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Jeffrey S. Miller

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

author name string

E D Warlick

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Q Cao

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

publication date

28 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1789-1791

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.61

21 January 2018

Preferential induction of apoptosis for primary human leukemic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.61

21 January 2018

M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.61

21 January 2018

Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.61

21 January 2018

Phase I study of bortezomib in refractory or relapsed acute leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.61

21 January 2018

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.61

21 January 2018

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.61

21 January 2018

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.61

21 January 2018

SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.61

21 January 2018

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.61

21 January 2018

Bortezomib for AL amyloidosis: moving forward

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.61

21 January 2018

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.61

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.61

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2013.61

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44795969&oldid=2206927668"